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Summary
The individual importance of each of the four vitamin K-
dependent clotting factors on the generation of prothrombinase
activity in the plasma of orally anticoagulated patients has been
investigated.
Addition of purified factors VlI, IX or X to plasma from
deeply anticoagulated patients (International Normalized Ratio
2.8-4.8) did not influence the amount of prothrombinase activity
or the amount of thrombin formed. Only the prothrombin level in
the plasma determines the course of thrombin generation. Addi-
tion of increasing amounts of purified factor II, VII, IX or X to
plasmas deficient in respectively factor II, VII, IX or X showed
that the prothrombinase activity increases linearily with the
concentration of factor II added and that the concentration below
which the factors VII, IX and X start to have a measurable effect
on prothrombinase activity are 5oh, 207o and 30%, respectively.
Half maximal prothrombinase activity was found at about 1%
factor VII, 5"h factor IX and 8"/" factor X respectively.
From these observations we conclude that prirnarily the
variation in factor II level determines thrombin generation and
hence presumably the antithrombotic effect of oral anticoagulant
therapy. It therefore seems likely that, for the control of oral
anticoagulant therapy, tests that reflect factor II activity would be
suitable.
Introduction
The vitamin K-dependent coagulation proteins i.e. prothrom-
bin and factors VII, IX and X, are synthesized in the hepatic
parenchymal cells and have the common characteristic of the
occurrence of y-carboxylated glutamic acid residues in the N-
terminal region of the protein chain. The carboxylated coagula-
tion proteins are capable ^of binding to negatively charged
phospholipid surfaces via Ca'--bridges, this interaction is essen-
tial for their effective participation in the coagulation process (1).
Oral anticoagulation by coumarin congeners, interferes with
vitamin K-dependent carboxylation. This results in the synthesis
of immunologically detectable forms that are biologically inactive
or even inhibitory (2, 3). The formation of three multicomponent
enzymatic complexes of the coagulation cascade, i. e. the extrinsic
factor X activator (thromboplastin and factor VII.) the intrinsic
factor X activator (FIX.-FVIII.-PL) and prothrombin converting
activity (prothrombinase, FX.-FV"-PL) will be diminished by
oral anticoagulant therapy. This, as well as the decrease of
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prothrombin may contribute to the diminution of thrombin
generation observed in blood from anticoagulated patients.
The effect of coumarin therapy is not immediate. The preexis-
tant circulating clotting factors have to disappear before the level
of clotting factors adapts to the new diminished level of synthesis.
The various factors decline with velocities dependent upon their
half-life times which are approximately: factor VII: 6 hours,
factor IX: 14 hours, factor X: 45 hours, factor II: 60 hours (4).
Shortly after the beginning of anticoagulant therapy the levels of
clotting factors will show the following order: VII <lX <X <II.
Only when factor II, has adapted to the prevailing level of
synthesis the relative levels will be equal (5). If the therapy is
stopped the velocity of reappearance is again a function of half-
life time and the order will be VII >IX >X )II. Because of
fluctuations in dosage and (patho)physiological circumstances,
that influence the half life of the factors (metabolic status, body
temperature) stable anticoagulation with all factors at the same
level is less common than would be desirable. Therefore knowl-
edge of the relative importance of the level of each individual
clotting factor to the overall anticoagulant (i.e. antithrombotic)
effect is of great practical importance.
For an effective anticoagulant effect the levels of the vitamin
K-dependent clotting factors have normally to be decreased to
abort2}"/o of the normal level (6). The estimation of the potential
clotting activity is usually based on an overall clotting test of the
"prothrombin time" type. The relative contribution of the indi-
vidual clotting factors to this "hypocoagulability" of plasma is not
clearly understood. In this article we report the determination of
the relative importance of each of the vitamin K-dependent
coagulation factors for the diminution of prothrombin conversion.
Patients, Materials, and Methods
Patients
46 patients with a variety of thrombotic disorders undergoing oral
anticoagulation with dicoumarol drugs were selected for this study All
patients were in the optimal therapeutic range (I.S.R. 2.8-4.8) as judged
by the routine thrombotest estimation in the Maastricht Thrombosis
Service
Plasmas
Blood from patients undergoing oral anticoagulant treatment was
collected in trisodium citrate (9 volumes of blood to 1 volumc of 0 13 M
trisodium citrate) and centrifugated twice for 15 minutes at 3,000 x g at
15' C Plasma samples from the 46 patients were pooled and centrifugated
for I hour at 23,000 x g aI 4" C. The pooled platelet free plasma was
stored at -80" C. Factor II, VII, IX and X deficient plasmas were obtained
from Gencral Diagnostics.
Thromboplastin
Human brain thromboplastin was prepared by a modification of the
method of Owren and Aas (7) The pteparation obtained was
homogenized in a Potter Elvehjem homogeniser for 3 minutes, centritu-
gated at 2,000 x g fbr 15 minutes and stored in 0.1 ml aliquots at-20' C.
Prior to use the preparation was thawed, diluted 1 : 40 with 0.05 M Tris-
HC1 (pH 7.35) containing 0.1 M CaCl2 and prewarmed at 37' C for t hour.
When normal plasma was incubated with this thromboplastin dilution
under the same experimental conditions as used in the thrombin genera-
tion experiments the clotting time was 80 seconds.
Cephaloplnstin
Cephaloplastin was obtained from Dade (Aguada, Puerto Rico, USA).
The commercial reagent was diluted 1 : 5 with 0.05 M Tiis-HCl (pH 7.35)
containing 0.1 M CaCl2, prewarmed for 10 minutes at 37" C and mixed
befbre use.
Proteins
Human prothrombin and factor X were prepared as described by
Lindhout et al. (8). Human factor IX was prepared analogously to the
method of Fujikawa et al. (9). Human factor VII was kindly supplied by
Dr C. Reutelingsperger.
Commercial Reagents
Human congenital deficient plasmas were obtained from the Behring
Institute (West Germany) Soybean trypsin inhibitor (SBTI) was obtained
from Sigma (St Louis, USA). The chromogenic substrate 52238 was
obtained from Kabi Vitrum (Stockholm, Sweden). A11 other chemicals
were of the highest grade commercially available.
Measurement of Clotting Factor II, VII, IX and X Activities in Dicoumarol
Plasma
The activity levels of the clotting factors II, VII, IX and X in
dicoumarol plasma were quantitatively determined by a standard one-
stage method using either congenitally deticient plasma prepared as
described above (factors IX and X) or commercially obtained deficient
plasma (Behring Werke, FRG). The method is described in ref. 7
Measurement of Thrombin Generation in Plasma
For the measurement of thrombin generation the procedure described
by Hemker et al. (10) was used. Briefly, 240 pl of plasma and 60 pl of
buffer (Tiis-HCl, pH 7.35) were incubated for 4 minutes at 37' C
Thrombin generation was triggered by the addition of 60 pl of 0 1 M
CaCl2 solution containing a suitable trigger of coagulation For activation
of the extrinsic pathway the trigger consisted of thromboplastin (final
dilution 71240) and for activation of the intrinsic pathway Cephaloplastin
(final dilution 1/30) was used At fixed time intervals, 10 pl aliquots of the
incubation mixture were subsampled into a tcst tube containing 465 pl of
buffer (Tiis-HCl, 0 t M NaCl, 0.5% albumin, 0.02 M EDTA. pH 7.9) and
25 pl of 52238 (a mM) a|37" C Thcse tubes were incubated for 2 minutes
ar 37' C, and then the reaction was stopped by the addition of 300 pl of
concentrated acetic acid The pipettes used for sampling and stopping the
reaction were connected to an Apple IIe computer, programmed to
record the moment of sampling and the moment of stopping the reaction.
The optical density was read at 405 nm in a spectrophotometer (LKB-
Ultraspec ). From the change in optical density and the time interval
between sampling and stopping the O D./min was automatically calcu-
lated.
Measurement of the Decay Constant of Endogenous Thrombin and the
Course of Prothrombinase Activity
Briefly, 120 pl of plasma and 24 p.l of buffer (Tiis-HCl, pH 7.35) were
incubated for 4 minutes at 37" C Thrombin generation was triggered by
the addition of 30 pl of thromboplastin Two minutcs after maximal
thrombin formation, 6 pl of Soybean Tiypsin Inhibitor (SBTI, 10 mg/ml)
were added to the incubation mixturc. As quickly as possible after the
addition of SBTI, 10 pl aliquots of the incubation mixturc wcre sub-
sampled into a test tube containing 52238 (4 mM) and EDTA (20 mM) by
using the time recording pipette. The measuring procedurc was the same
as that described for the measurement of thrombin generation (9)
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Fig I Effect on thrombin generation of the addition of various amounts
of factor II to dicoumatol plasma. Coagulation was triggered with
thromboplastin (final dilution Il24$. a:4 pM; O: 2.75 tt'M1, A: 1.5 pM;
A: t  pM; ! :  0.66 pM; I :  0.33 pM.
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Fig.2 Effect on prothrombinasc of the addition of various amounts of
factor Il, VII, IX and X to dicoumarol plasma Coagulation was triggered
with thromboplastin (final dilution 11240). (Factors VII and X) or with
Cephaloplastin (final dilution 1/30). (Factor IX) The points rcpresent the
maximal prothrombinasc activity calculated from thc thrombin gencration
curves. O: factor II; O: factor VII; A: factor IX; A: factor X
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Fig 3 Effcct on prothrombinase of the addition of various amounts of
factor VII, IX and X to congenital dcficient plasma. Coagulation was
triggered with thromboplastin (final dilution 1/240). (Factors VII and X)
or with Cephaloplastin (final dilution 1/30). (Factor IX) The points
represent the maximal prothrombinase activity calculated from the
thrombin gcneration curves O: factor II; O: factor VII; A: factor IX;
A: factor X
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The data obtained from thrombin amidolytic activity at the different
time points (C) were fitted to the formula Ct : Cn * Coe (k' + k)t which
gives the level at the moment of SBTI addition (C. + CR), the steady end
level (Cp) and the decay constant (k). The parameters were determined
by means of an ordinary least squares fit of the model to the data. The
parameter values that minimize the sum of squared residuals were
calculated using the Box-Kanemasu modification of Gauss' method. The
linear equations were solved by means of Haussholder transformations.
The decay constant thus obtained is the sum of the u2-macroglobulin
dependent decay constant (k2) and the antithrombin III dependent decay
constant (k1). The ratio of k1 to k2 was obtained from the ratio of
antithrombin III bound thrombin to o2-macroglobulin bound thrombin.
The time course of prothrombinase activity (nM min r) was calculated
by computer, using the thrombin generation curve and the experimentally
determined decay constants of endogenous thrombin. For full technical
details see ref. 10.
Results
Time Course of Thrombin Generation and Prothrombinase
Formation in Normal and Dicoumarol Plasmas
The levels of factor II. factor VII. factor IX and factor X
activity in the pooled dicoumarol plasma were 22o/", l0%, 40%
and 197" respectively (i.e. approximatively 330, l, 30 and
33 nM). The decay constants k1 and k2 were estimated as 0.938 +
0.017 and as 0.232 + 0.004 min r resp. (n : 25). Thrombin
generation and prothrombinase formation in the dicoumarol
plasma after triggering coagulation with thromboplastin as well as
after triggering coagulation with Cephaloplastin were decreased
to a similar degree (- 20%, results not shown).
To determine which of the vitamin K-dependent coagulation
factors is responsible for the decreases of thrombin generation
and prothrombinase activity, we investigated the effect of the
addition of increasing amounts of respectively factor II, factor
VII, factor IX or factor X to dicoumarol plasma. For studying the
effects of factor II, factor VII and factor X, coagulation was
triggered with thromboplastin and for studying the effect of fac-
tor IX coagulation was triggered with Cephaloplastin.
Fig. 1 shows the effect on thrombin generation of the addition
of increasing amounts of factor II to dicoumarol plasma. From
these and similar curves the course of prothrombinase activity was
calculated. From Fig.2 rt is seen that peak prothrombinase
activity increases directly proportional to the concentration of
factor II added to the plasma. Theoretically we should expect a
saturation phenomenon at high factor II levels. Even 4 trrM of
factor II, more than a twice the physiological concentration
showed a prothrombinase activity of 740 nM/min indicating that
even this amount is still far from the saturating concentration.
Fig.2 also shows the effects on peak prothrombinase activity of
the addition of factor VII, factor IX and factor X to dicoumarol
plasma. Neither the thrombin generation (not shown) nor the
prothrombinase formation could be stimulated by the addition of
these factors. Evidently the amount present in the dicoumarol
plasma is sufficient to form the necessary prothrombinase.
Effects on Prothrombinase Formation of the Addition of Factor II,
Factor VII, Factor IX and Factor X to Congenital Deficient
Plasmas
In order to assess the levels below which the factors VII, IX
and X start to have an influence on prothrombin conversion, we
performed further experiments in which the.effect of the addition
of a various amounts of the four vitamin K-dependent clotting
factors to congenital deficient plasmas was studied. The results of
these experiments are summarized in Fig.3.
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As could be expected from the experiment reported in Fig.2
the peak prothrombinase activity increases linearly with the
amounts of factor II present in the plasma. The factors VII, IX
and X start to have a recognisable effect on prothrombinase
activity when their levels fall below 5%, 20Y" and 30%, respec-
tively. Half maximal prothrombinase activity is found roughly at
87" for factor VII, 5T" for factor IX and 10% for factor X.
Discussion
The hypocoagulability of dicoumarol plasma is due to the
diminution of the effective coagulation activity of one or more of
the four vitamin K-dependent clotting factors: prothrombin,
factor VII, factor IX and factor X. Oral anticoagulant therapy is
usually monitored by prothrombin time type tests. Therapeutic
levels are defined by the extent to which the prothrombin time is
prolonged, normalized to the international normalized ratio
(I.N.R:) according to an international convention (11). Oral
anticoagulant therapy influences the effective concentration of
three factors that influence the prothrombin time (prothrombin,
factor VII and factor X). One fixed clotting time can therefore
represent an infinite variety of combinations of concentrations of
these three clotting factors. There is no a priori reason to assume
that the therapeutic effect of anticoagulant therapy finds true-to-
life rendering in the prolongation of the prothrombin time. On
the other hand one may well assume that the inhibition of the
capacity to generate thrombin is directly related to the therapeutic
effect. Were it only because two completely dissimilar but equally
effective families of antithrombotic drugs like the heparins and
the coumarin congeners have no other known common charac-
teristic then their antithrombin activity only.
In the initial period of oral anticoagulant therapy a reduction of
the factor VII activity may be expected to determine the
prothrombin time while after a longer period of time the effective
response will probably depend on the reduced factor X and/or
prothrombin activity. The exact mechanism of the development
of the antithrombotic effect by diminution of clotting factors is
unknown. Clinical experience has empirically teached us to keep
the plasma thromboplastin time at a certain level in order to
provide protection against thrombosis with a minimal risk of
hemorrhagic complications (11).
In an attempt to better understand the relative contribution of
the different vitamin K-dependent clotting factors to the thrombin
generating activity, we first, by addition of purified vitamin K-
dependent clotting factors to dicoumarol plasma, determined
what factors were rate limitiqg in this process. We found that only
the prothrombin level originally present in the dicoumarol plasma
determines the course of thrombin generation (Fig.2). The
prothrombinase activity formed (about 20"/" of normal) in
dicoumarol plasma was sufficienl to catalyze the conversion of
twice or more the normal amount of prothrombin into thrombin.
The addition of the factors VII, IX or X to dicoumarol plasma did
not promote thrombin generation. This implicates that, during
the initial and the intermediate stages of oral anticoagulant
therapy, a prolonged in vitro prothrombin time caused by a
reduced activity of the factors \|II and X does not adequately
reflect the thrombin generation potency of the plasma. lndeed it
means that a high factor Vll-sensitivity or factor X sensitivity of a
thromboplastin tends to obscure the physiological effect of oral
anticoagulation.
Our type of approach does not take into account the effect of
oral anticoagulation on proteins C and S. We therefore do not
claim that the measurement of prothrombin alone will under all
circumstances adequately measure the in vivo effects of this
treatment. They do show, however, that prothrombin is the most
important factor among those that influence the laboratory tests
used for monitoring oral anticoagulant therapy.
In order to find out below which level(s) the vitamin K-
dependent clotting factors start to have an effect on prothrombin-
ase activity, we studied the effect of the addition of the purified
vitamin K-dependent clotting factors to congenital deficient
plasmas. It was shown that the prothrombinase activity linearily
increases with the concentration of prothrombin and that the
factors VII, IX and X start to have an effect on the prothrombin-
ase activity when the concentrations were lower than 5%, 20%
and 30"/., respectively. A half maximal prothrombinase activity is
found at abort2"/" (factor VII), 6% (factor IX) and 10% (factor X)
(Fig.3). It can be concluded that both the optimal factor X
converting activity (tenase) and the optimal prothrombin convert-
ing activity (prothrombinase) only require small amounts of the
enzymes (factor IXu and factor Xu). Also, for triggering the
thromboplastin-dependent pathway, only a small amount of
factor VII is needed.
In discussing these results it must be recognized that the
experiments have been carried out at concentrations of tissue
factor that may be lower then the amount of factor VII available.
Because the factor VII - tissue factor complex is characterized by
a 1 : 1 stoichiometry this means that at higher thromboplastin
concentrations factor VII might more readily become rate limit-
ing We might therefore limit the import of this study to the use of
commercial thromboplastins such as used in the practise of
anticoagulant control.
On the other hand it may be argued that this type of
thromboplastin concentrations probably is relatively high com-
pared to those encountered in physiology. We have shown that
the factor VII dependent activation of factor IX starts to play a
role at thromboplastin concentrations that are more then tenfold
lower then those used here /12). lf we admit that the anti-
hemophilic factors are important for normal physiological throm-
bin generation and that these factors excert their physiological
function in the factor VII - factor IX (+ VIII) - factor X pathway
rather then in the classical intrinsic pathway (13) then it necessar-
ily follows that for physiological thrombin generation the prevail-
ing tissue factor concentrations are probably much lower than
those used in our experiments. In that case the factor VII
dependancy of our experiments would not be unrealistic. A
precise quantitative approach of this question will be possible only
with the use of highly purified or recombinant tissue factor that
was not available in our laboratory.
We conclude that the principal effect of oral anticoagulant
therapy on the thrombin generation potential is achieved by its
influencing the effective prothrombin level. We therefore think
that it may be interesting to use an assay that monitors the
effective prothrombin level for the control of oral anticoagulant
therapy.
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